Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
152 hedge funds and large institutions have $1.26B invested in Acorda Therapeutics in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 61 increasing their positions, 40 reducing their positions, and 17 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 40
26% more capital invested
Capital invested by funds: $1B → $1.26B (+$258M)
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
1% more funds holding
Funds holding: 151 → 152 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
19% less call options, than puts
Call options by funds: $6.72M | Put options by funds: $8.28M
Top Buyers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$32.1M |
| 2 |
SCM
Scopia Capital Management
New York
|
+$27.5M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$15.4M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$11.4M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.45M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$20.3M |
| 2 |
CI
Cambiar Investors
Denver,
Colorado
|
-$11.8M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$7.88M |
| 4 |
State Street
Boston,
Massachusetts
|
-$6.39M |
| 5 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$4.94M |
ACOR Hedge Fund Activity: Q3 2017 in Review
152 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2017, worth a combined $1.26B — up 26% from $1B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ACOR positions and 17 closed out — a net gain of 1 holder — while 61 added to existing stakes and 40 trimmed.
The largest buyer was PFM Health Sciences, adding an estimated $32.1M. The largest seller was Citadel Advisors, cutting an estimated $20.3M.
- 152 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2017, up from 151 in Q2 2017.
- Funds reported $1.26B of Acorda Therapeutics stock for Q3 2017, up 26% quarter-over-quarter.
- 18 funds opened new Acorda Therapeutics positions in Q3 2017 and 17 closed out, a net change of +1 holder.
- The largest Acorda Therapeutics buyer in Q3 2017 was PFM Health Sciences, an estimated $32.1M added.
- The largest Acorda Therapeutics seller in Q3 2017 was Citadel Advisors, an estimated $20.3M sold.
Based on aggregated 13F filings for Q3 2017.